NASDAQ:FIXX Homology Medicines (FIXX) Stock Price, News & Analysis → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free FIXX Stock Alerts $16.82 +0.13 (+0.77%) (As of 03/25/2024) Add Compare Share Share Today's Range$16.20▼$17.5150-Day Range$0.33▼$16.8252-Week Range$0.46▼$17.51Volume22,300 shsAverage Volume390,307 shsMarket Capitalization$978.01 millionP/E RatioN/ADividend YieldN/APrice Target$0.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Homology Medicines alerts: Email Address Homology Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside95.5% Downside$0.75 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to ($0.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.46 out of 5 starsMedical Sector858th out of 908 stocksPharmaceutical Preparations Industry405th out of 424 stocks 1.3 Analyst's Opinion Consensus RatingHomology Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHomology Medicines has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for FIXX. Previous Next 0.0 Dividend Strength Dividend YieldHomology Medicines does not currently pay a dividend.Dividend GrowthHomology Medicines does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHomology Medicines has received a 78.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Homology Medicines is -0.33. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Homology Medicines insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Homology Medicines is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHomology Medicines has a P/B Ratio of 13.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchControversial CEO explains new way to amass wealthThere's no shortage of controversial CEOs in America today... From Elon Musk... to Disney's Bob Iger... to JP Morgan's Jamie Dimon... But only one controversial CEO that I know of is willing to show you exactly how and why he cut his annual salary to $1...Don't miss Porter's brand-new presentation on this subject About Homology Medicines Stock (NASDAQ:FIXX)Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Read More FIXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FIXX Stock News HeadlinesApril 30, 2024 | americanbankingnews.comHomology Medicines (NASDAQ:FIXX) Stock Price Up 0.8%March 24, 2024 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Declares Distribution to Common StockholdersMay 7, 2024 | InvestorPlace (Ad)This is the ONLY AI story you should be worried aboutA.I. is creeping into every aspect of our daily lives… According to billion-dollar fund manager, Louis Navellier, it’s never been more important to A.I.-proof your wealth. He lays out three simple steps to take ASAP in his latest video.March 23, 2024 | seekingalpha.comFIXX Homology Medicines, Inc.March 18, 2024 | finance.yahoo.comHomology Medicines Declares Distribution to Common StockholdersFebruary 27, 2024 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXFebruary 2, 2024 | investing.comHomology Medicines Inc (FIXX)January 4, 2024 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyMay 7, 2024 | InvestorPlace (Ad)This is the ONLY AI story you should be worried aboutA.I. is creeping into every aspect of our daily lives… According to billion-dollar fund manager, Louis Navellier, it’s never been more important to A.I.-proof your wealth. He lays out three simple steps to take ASAP in his latest video.January 4, 2024 | msn.comHomology Medicines gets non-compliance notice from NasdaqJanuary 3, 2024 | finance.yahoo.comHomology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price DeficiencyDecember 27, 2023 | benzinga.comHomology Medicines Stock (NASDAQ:FIXX) Insider TradesDecember 27, 2023 | benzinga.comHomology Medicines Stock (NASDAQ:FIXX), Short Interest ReportNovember 21, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXXNovember 17, 2023 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXNovember 17, 2023 | businesswire.comHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXNovember 17, 2023 | bizjournals.comBig Pharma-backed startup to go public by merging with gutted HomologyNovember 16, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (FIXX), Align Tech (ALGN) and Calidi Biotherapeutics (CLDI)November 16, 2023 | msn.comHomology Medicines slumps after merger deal with Q32 BioNovember 16, 2023 | msn.comWhy Is Rare Disease Focused Homology Medicines Stock Trading Lower Today?November 16, 2023 | tmcnet.comFIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to ShareholdersNovember 16, 2023 | marketwatch.comHomology Medicines Shares Drop 38% After Buyout Offer From Q32 BioNovember 16, 2023 | markets.businessinsider.comHomology Medicines To Merge With Q32 Bio; Homology Medicines Down In Pre-marketNovember 16, 2023 | finance.yahoo.comQ32 Bio and Homology Medicines Announce Merger AgreementNovember 15, 2023 | finanznachrichten.deHomology Medicines, Inc.: Homology Medicines Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | msn.comHomology Medicines GAAP EPS of -$0.57 misses by $0.15November 14, 2023 | finance.yahoo.comHomology Medicines Reports Third Quarter 2023 Financial ResultsSee More Headlines Receive FIXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/07/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FIXX CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone(781) 301-7277FaxN/AEmployees7Year Founded2015Price Target and Rating Average Stock Price Target$0.75 High Stock Price Target$0.75 Low Stock Price Target$0.75 Potential Upside/Downside-95.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net Margins-4,779.31% Pretax Margin-7,532.87% Return on Equity-102.52% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales843.12 Cash FlowN/A Price / Cash FlowN/A Book Value$1.26 per share Price / Book13.35Miscellaneous Outstanding Shares58,130,000Free Float48,774,000Market Cap$978.01 million OptionableOptionable Beta-0.10 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Paul Alloway J.D. (Age 52)Ph.D., President & COO Comp: $661.45kDr. Saswati Chatterjee Ph.D.Co-Founder & Member of Scientific Advisory BoardMr. Charles Michaud Jr.CPA, VP of Finance, Corporate Controller & TreasurerMs. Theresa McNeely (Age 60)Chief Communications Officer & Patient Advocate Key CompetitorsLiquidiaNASDAQ:LQDACassava SciencesNASDAQ:SAVAABIVAX Société AnonymeNASDAQ:ABVXMacroGenicsNASDAQ:MGNXCentessa PharmaceuticalsNASDAQ:CNTAView All CompetitorsInsiders & InstitutionsADAR1 Capital Management LLCBought 293,676 shares on 2/14/2024Ownership: 0.508%George Kaiser Family FoundationBought 267,194 shares on 2/12/2024Ownership: 0.530%Arthur TzianabosSold 26,074 sharesTotal: $7,431.09 ($0.29/share)Paul AllowaySold 14,560 sharesTotal: $4,149.60 ($0.29/share)Albert SeymourSold 2,896 sharesTotal: $1,665.20 ($0.58/share)View All Insider TransactionsView All Institutional Transactions FIXX Stock Analysis - Frequently Asked Questions Should I buy or sell Homology Medicines stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FIXX shares. View FIXX analyst ratings or view top-rated stocks. What is Homology Medicines' stock price target for 2024? 2 Wall Street analysts have issued 1 year price targets for Homology Medicines' stock. Their FIXX share price targets range from $0.75 to $0.75. On average, they predict the company's stock price to reach $0.75 in the next twelve months. This suggests that the stock has a possible downside of 95.5%. View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts. How have FIXX shares performed in 2024? Homology Medicines' stock was trading at $0.3040 at the beginning of 2024. Since then, FIXX stock has increased by 5,434.4% and is now trading at $16.8246. View the best growth stocks for 2024 here. When is Homology Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FIXX earnings forecast. How were Homology Medicines' earnings last quarter? Homology Medicines, Inc. (NASDAQ:FIXX) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.30) by $0.03. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%. When did Homology Medicines' stock split? Homology Medicines's stock split before market open on Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly created shares were payable to shareholders after the closing bell on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Homology Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO). When did Homology Medicines IPO? Homology Medicines (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Homology Medicines? Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FIXX) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Homology Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
